36 results about "Aminopherase" patented technology

The invention discloses a traditional Chinese medicine composition used for curing chronic hepatitis and a preparation method thereof. The traditional Chinese medicine composition is made of raw material medicines with the weight proportion by parts: 40 to 160 parts of Chinese thorowax root, 40 to 160 parts of debark peony root, 40 to 160 parts of angelica, 40 to 160 parts of India madder root, 40 to 160 parts of largehead atractylodes rhizome, 40 to 160 parts of Tuckahoe, 40 to 160 parts of turtle carapace, 40 to 160 parts of massa medicata fermentata hunanensis, 60 to 240 parts of Codonopsis pilosula nannfeldt, 60 to 240 parts of Lalang Grass Rhizome, 24 to 96 parts of immature orange fruit, 20 to 80 parts of green tangerine peel, 12 to 48 parts of villous amomum fruit, 12 to 48 parts of earthworm and 12 to 48 parts of liguorice. The traditional Chinese medicine composition of the invention has the pharmacological efficacies of antagonizing hepatic damage, protecting liver, regulating immune function, reducing aminopherase, improving liver function and on the like, and the clinical efficacy observation experiments prove that the traditional Chinese medicine composition has the exact efficacies to the chronic hepatitis, in particular to chronic active hepatitis, chronic persisting hepatitis and early cirrhosis; and the clinical application is of safety and no toxicity and side effects.

The invention discloses an application of novel aminopherase and a high-vitality mutant thereof to asymmetric synthesis of L-glufosinate-ammonium. The amino acid sequence of the aminopherase is as shown in SEQ ID:1, and the mutant of the aminopherase is prepared through performing single-site mutation or multi-site mutation on one or a plurality of 87th, 108th, 167th, 304th and 357th in the aminoacid sequence as shown in the SEQ ID:1. The high-efficiency expression of vitality mutant genes of high-conversion rate aminopherase can be realized, and the highest enzyme activity is 818.4U / mg. Thehighest optimum reaction temperature of the aminopherase vitality mutant can reach 67 DEG C, and during asymmetric synthesis of the L-glufosinate-ammonium through catalyzing 800mM of glufosinate-ammonium precursor ketone at the temperature, the conversion rate is as high as 100%. The NsTA mutant solves the technical difficult problems that few enzyme sources exist, the enzyme activity is low, substrate tolerance is bad and the conversion rate is low in a current L-glufosinate-ammonium preparation technology from the aminopherase, and has better application prospects.

The invention discloses a low-temperature activity treatment technology of flavor freshwater fish, which comprises the steps of fresh fish selection and pretreatment, fish meat rinsing and draining, stirring of fish meat and ingredients, dewatering and drying in a drying warehouse, vacuum packing and the like. According to the treatment technology, a specially-made system, and control and adjustment of a technological parameter allow fresh fish to be dewatered and dried at a lower drying temperature (5-10 DEG C) quickly, so that a unique flavor is formed, and a sanitary condition is improved greatly; a centrifugal fan in the system exchanges air quickly, and a dryer dries and dehumidifies the air, so that the indoor air can be kept in a compulsory circulation state all the time, and water evaporation of a material is facilitated; the freshwater fish is subjected to protein crosslinking by glutamoyl aminopherase, so that the flavor and a taste of the freshwater fish are further improved; and the machining time of the freshwater fish is shortened to be 30h from the existing approximate 80h, so that a production cycle is shortened, and the production efficiency is improved, and a good economic benefit is exerted.

The invention discloses a schizandrol dripping pills for decreasing aminopherase and method for preparing. The objective of the invention is to provide a medicinal composition having the advantages of high biological availability, quick-speed medicine release, quick-speed effect, higher medicinal content, easy administration, low price, and causing no pollution during production. The drop pill is prepared from schizandrol concrete as raw material, and medicinal carrying agent as the base material.

The invention discloses an alanine aminotransferase monoclonal antibody and an application, belonging to the medicine product containing antibody or the preparation of monoclonal antibody. The invention has the specificity of anti human alanine aminotransferase, which is generatd by hybridoma cell whose preservation number is CGMCC No2232. The invention uses purified ALT antigen to immunize BALB / C mice, fuses spleen cells and SP2 / 0 myeloma cells, uses indirect ELISA to screen hybridoma cell, grafts in mice abdominal, collects and purifies McAb ascetic fluid, to obtain anti human ALT specific ALT monoclonal antibody. The inventive product can be used to check alanine aminotransferase of serum. The product an specifically recognize ALT in serum without cross reaction with other proteins in serum, but with better infinity, thereby providing necessary condition for simple, quick and specific ALT immunity analysis.

The invention relates to a method to make protease in enzyme by restrain glutamine aminopherase fermenting method that belongs to enzyme technology field. The invention uses glutamine aminopherase fermenting to make enzyme. And during the manufacturing process, the metal ion inhibitor would be added and the activity of protease would be restrained. The invention is easy to operate and high efficiency.